Time to Surgery and Survival Outcomes for Patients With Resected Colorectal Carcinoma: Multicenter Study (BIG RENAPE)
Launched by INSTITUT CANCEROLOGIE DE L'OUEST · Jun 4, 2021
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
This is a retrospective study including exhaustively all patients operated CC0-CC1 of peritoneal carcinosis between 2007 and 2019 meeting the inclusion criteria:
* Patients from the Institut de cancérologie de l'Ouest and the CHU of Lyon for the study period 2007-2016
* Patients included in the BIG-RENAPE network between 2016 and 2019
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age \>18 years
- • 2. Histological evidence of peritoneal metastases
- • 3. Primary colorectal cancer
- • 4. Surgical cytoreduction CC0 or CC1
- Exclusion Criteria:
- • 1. Patient who has not received at least 3 courses of pre and/or post cytoreduction chemotherapy
- • 2. Primitive appendicitis
- • 3. Unknown primitive
- • 4. Patient with incomplete CC2 and/or palliative surgery
- • 5. Patient opposed to the use of their data for research.
- • 6. Isolated local pelvic recurrence.
- • 7. Extraperitoneal metastases not resected or destroyed before or during cytoreduction.
- • 8. Patient opposed to the use of his/her data for research purposes
About Institut Cancerologie De L'ouest
The Institut de Cancérologie de l'Ouest (ICO) is a leading French cancer research and treatment center dedicated to advancing oncology through innovative clinical trials and multidisciplinary care. As a key player in the fight against cancer, ICO integrates cutting-edge research with clinical practice, focusing on personalized medicine and patient-centered approaches. With a commitment to improving patient outcomes, ICO collaborates with academic institutions and industry partners to develop novel therapies and enhance understanding of cancer biology. The institute's expertise spans various cancer types, making it a pivotal hub for oncological research and education in France and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lyon, , France
Saint Herblain, , France
Patients applied
Trial Officials
Frédéric DUMONT, MD
Principal Investigator
Institut de Cancérologie de l'Ouest
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials